TY - JOUR AU - Lu, H. PY - 2014 DA - 2014// TI - TLR agonists for Cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects JO - Front Immunol VL - 5 ID - Lu2014 ER - TY - JOUR AU - Krieg, A. M. AU - Yi, A. K. AU - Matson, S. AU - Waldschmidt, T. J. AU - Bishop, G. A. AU - Teasdale, R. PY - 1995 DA - 1995// TI - CpG motifs in bacterial DNA trigger direct B-cell activation JO - Nature. VL - 374 UR - https://doi.org/10.1038/374546a0 DO - 10.1038/374546a0 ID - Krieg1995 ER - TY - STD TI - Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, et al. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017;2(18). ID - ref3 ER - TY - JOUR AU - Davila, E. AU - Kennedy, R. AU - Celis, E. PY - 2003 DA - 2003// TI - Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade JO - Cancer Res VL - 63 ID - Davila2003 ER - TY - JOUR AU - Mangsbo, S. M. AU - Sandin, L. C. AU - Anger, K. AU - Korman, A. J. AU - Loskog, A. AU - Totterman, T. H. PY - 2010 DA - 2010// TI - Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy JO - J Immunother VL - 33 UR - https://doi.org/10.1097/CJI.0b013e3181c01fcb DO - 10.1097/CJI.0b013e3181c01fcb ID - Mangsbo2010 ER - TY - JOUR AU - Sagiv-Barfi, I. d. i. t. AU - Czerwinski, D. e. b. r. a. K. AU - Levy, S. h. o. s. h. a. n. a. AU - Alam, I. s. r. a. t. S. AU - Mayer, A. a. r. o. n. T. AU - Gambhir, S. a. n. j. i. v. S. AU - Levy, R. o. n. a. l. d. PY - 2018 DA - 2018// TI - Eradication of spontaneous malignancy by local immunotherapy JO - Science Translational Medicine VL - 10 UR - https://doi.org/10.1126/scitranslmed.aan4488 DO - 10.1126/scitranslmed.aan4488 ID - Sagiv-Barfi2018 ER - TY - JOUR AU - Brody, J. D. AU - Ai, W. Z. AU - Czerwinski, D. K. AU - Torchia, J. A. AU - Levy, M. AU - Advani, R. H. PY - 2010 DA - 2010// TI - In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2010.28.9793 DO - 10.1200/JCO.2010.28.9793 ID - Brody2010 ER - TY - JOUR AU - Marabelle, A. AU - Kohrt, H. AU - Sagiv-Barfi, I. AU - Ajami, B. AU - Axtell, R. C. AU - Zhou, G. PY - 2013 DA - 2013// TI - Depleting tumor-specific Tregs at a single site eradicates disseminated tumors JO - J Clin Invest VL - 123 UR - https://doi.org/10.1172/JCI64859 DO - 10.1172/JCI64859 ID - Marabelle2013 ER - TY - JOUR AU - Davis, H. L. AU - Weeratna, R. AU - Waldschmidt, T. J. AU - Tygrett, L. AU - Schorr, J. AU - Krieg, A. M. PY - 1998 DA - 1998// TI - CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen JO - J Immunol VL - 160 ID - Davis1998 ER - TY - JOUR AU - Kapp, K. e. r. s. t. i. n. AU - Volz, B. a. r. b. a. r. a. AU - Oswald, D. e. t. l. e. f. AU - Wittig, B. u. r. g. h. a. r. d. t. AU - Baumann, M. a. t. t. h. i. a. s. AU - Schmidt, M. a. n. u. e. l. PY - 2019 DA - 2019// TI - Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors JO - OncoImmunology VL - 8 UR - https://doi.org/10.1080/2162402X.2019.1659096 DO - 10.1080/2162402X.2019.1659096 ID - Kapp2019 ER - TY - JOUR AU - Selby, M. J. AU - Engelhardt, J. J. AU - Quigley, M. AU - Henning, K. A. AU - Chen, T. AU - Srinivasan, M. PY - 2013 DA - 2013// TI - Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells JO - Cancer Immunol Res. VL - 1 UR - https://doi.org/10.1158/2326-6066.CIR-13-0013 DO - 10.1158/2326-6066.CIR-13-0013 ID - Selby2013 ER - TY - JOUR AU - Curran, M. A. AU - Allison, J. P. PY - 2009 DA - 2009// TI - Tumor vaccines expressing Flt3 ligand synergize with CTLA-4 blockade to reject Preimplanted tumors JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-3289 DO - 10.1158/0008-5472.CAN-08-3289 ID - Curran2009 ER - TY - JOUR AU - Curran, M. A. AU - Kim, M. AU - Montalvo, W. AU - Al-Shamkhani, A. AU - Allison, J. P. PY - 2011 DA - 2011// TI - Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production JO - PLoS One VL - 6 UR - https://doi.org/10.1371/journal.pone.0019499 DO - 10.1371/journal.pone.0019499 ID - Curran2011 ER - TY - STD TI - Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, et al. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest. 2018. ID - ref14 ER - TY - JOUR AU - Ager, C. R. AU - Reilley, M. J. AU - Nicholas, C. AU - Bartkowiak, T. AU - Jaiswal, A. R. AU - Curran, M. A. PY - 2017 DA - 2017// TI - Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity JO - Cancer Immunol Res VL - 5 UR - https://doi.org/10.1158/2326-6066.CIR-17-0049 DO - 10.1158/2326-6066.CIR-17-0049 ID - Ager2017 ER -